Crossmark

Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis

Crossref DOI link: https://doi.org/10.1136/rmdopen-2022-002795

Published Online: 2023-01-02

Published Print: 2023-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ida, Tomoaki https://orcid.org/0000-0002-8023-336X
Furuta, Shunsuke

Takayama, Asuka

Tamura, Jun

Hayashi, Yuki

Abe, Kazuya

Kurihara, Syunjiro

Ishikawa, Junichi

Iwamoto, Taro https://orcid.org/0000-0003-1663-3518
Ikeda, Kei https://orcid.org/0000-0003-0574-9611
Suzuki, Kotaro https://orcid.org/0000-0002-4692-2970
Nakajima, Hiroshi https://orcid.org/0000-0001-8595-9381
License Information

License valid from 2023-01-02